awmsg logo



tiotropium (Spiriva® Respimat®)


Reference No. 3436

Publication date:
19/10/2017


Appraisal information

tiotropium (Spiriva® Respimat®) 2.5 microgram inhalation solution


Company: Boehringer Ingelheim Ltd
BNF category: Respiratory system
NMG meeting date: 06/09/2017
AWMSG meeting date: 11/10/2017
   
   
Submission Type: Resubmission
Status: Recommended
Advice No: 2317
Ministerial ratification: 18/10/2017

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Tiotropium (Spiriva® Respimat®) is recommended as an option for use within NHS Wales as an add-on maintenance bronchodilator treatment in adult patients with asthma who are currently treated with the maintenance combination of inhaled corticosteroids (≥ 800 micrograms budesonide daily or equivalent) and long acting beta2-agonists and who experienced one or more severe exacerbations in the previous year.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download